Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Macrogenics (MGNX) Common Equity (2016 - 2025)

Historic Common Equity for Macrogenics (MGNX) over the last 14 years, with Q3 2025 value amounting to $67.0 million.

  • Macrogenics' Common Equity fell 4419.65% to $67.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $67.0 million, marking a year-over-year decrease of 4419.65%. This contributed to the annual value of $116.1 million for FY2024, which is 2395.34% down from last year.
  • As of Q3 2025, Macrogenics' Common Equity stood at $67.0 million, which was down 4419.65% from $46.6 million recorded in Q2 2025.
  • Macrogenics' 5-year Common Equity high stood at $350.5 million for Q1 2021, and its period low was $46.6 million during Q2 2025.
  • Over the past 5 years, Macrogenics' median Common Equity value was $142.0 million (recorded in 2022), while the average stood at $158.2 million.
  • In the last 5 years, Macrogenics' Common Equity skyrocketed by 8393.53% in 2021 and then crashed by 6629.49% in 2024.
  • Over the past 5 years, Macrogenics' Common Equity (Quarter) stood at $239.6 million in 2021, then plummeted by 40.73% to $142.0 million in 2022, then rose by 7.46% to $152.6 million in 2023, then decreased by 23.95% to $116.1 million in 2024, then crashed by 42.27% to $67.0 million in 2025.
  • Its last three reported values are $67.0 million in Q3 2025, $46.6 million for Q2 2025, and $79.1 million during Q1 2025.